Evidence map›Paper›PMID 30289810›Full record

Observational studyAIDS (London, England)2018

Increase in HSV shedding at initiation of antiretroviral therapy and decrease in shedding over time on antiretroviral therapy in HIV and HSV-2 infected persons.

Emily S Ford, Amalia S Magaret, Cedric W Spak, Stacy Selke, Steve Kuntz, Lawrence Corey, Anna Wald

Abstract readObservational Study
In one paragraph

Observational study in AIDS (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Papillomatous Anogenital Lesions in a Patient With Human Immunodeficiency Virus.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Emily S FordDepartment of Medicine.
Amalia S MagaretDepartment of Laboratory Medicine.
Cedric W SpakSimmons Transplant Institute, Dallas.
Stacy SelkeDepartment of Laboratory Medicine.
Steve KuntzDepartment of Laboratory Medicine.
Lawrence CoreyDepartment of Medicine.
Anna WaldDepartment of Medicine.
Fred Hutch Cancer Center · USBaylor Scott & White All Saints Medical Center · USGTx (United States) · US

Funding

THE PERINATAL COMPLICATIONS OF ASYMPTOMATIC GENITAL HERPES SIMPLEX VIRUSP01AI030731 · NIAID · UNIVERSITY OF WASHINGTON · PI WALD, ANNA · 1991 to 2017
$34.3M
VENEREAL DISEASET32AI007140 · NIAID · UNIVERSITY OF WASHINGTON · PI Julia Cook Dombrowski · 1985 to 2026
$19.4M
Urethral microbiome and non-gonococcal urethritis in men who have sex with men (MU19AI113173 · NIAID · UNIVERSITY OF WASHINGTON · PI MARRAZZO, JEANNE M · 2014 to 2018
$14.3M
NIAID NIH HHS P01 AI030731NIAID NIH HHS T32 AI007140NIAID NIH HHS U19 AI113173
6 · The paper itself

Abstract

objectivesHIV-infected persons with chronic herpesvirus infections may experience paradoxical worsening after initiation of antiretroviral therapy (ART), but the impact of longer term ART is unclear. We evaluated the relationships between genital herpes simplex virus (HSV) shedding and ART initiation and time on therapy in HIV and HSV-2-infected persons.

designProspective observational study.

methodsRates of HSV shedding in 45 HIV and HSV-2-infected persons on or off ART were prospectively followed over up to three, noncontiguous, 60-day periods, during which participants performed daily genital swabs for HSV detection by real-time HSV DNA PCR and reported symptoms. Initiation or discontinuation of ART was at the discretion of participants' healthcare providers.

resultsIn all, 6425 daily genital swabs were obtained from 45 persons (38 men and seven women) during 105 swabbing sessions. During the three sessions, 67, 74, and 92% of persons were on ART. HSV was detected on 26.5% of days in men and 22.3% of days in women. The overall rates of genital HSV shedding were 19.4% of days in persons not on ART, 30.2% in persons within 90 days of ART initiation, and 23.3% in persons on ART for longer than 90 days. After initiation of ART, HSV shedding decreased by 2% per month, or 23% per year (RR 0.98/month on ART; P = 0.0003 in adjusted analysis). This finding was consistent after including consideration of HIV viral load and CD4 cell count.

conclusionsHSV shedding increased significantly shortly after ART initiation, but decreased with time on prolonged ART.

Indexed as

Virus SheddingAdultAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveDNA, ViralFemaleFollow-Up StudiesGenitaliaHerpes GenitalisHerpesvirus 2, HumanHIV InfectionsHumansMaleMiddle AgedProspective StudiesReal-Time Polymerase Chain ReactionAnti-Retroviral AgentsDNA, Viral

Identifiers

PMID30289810
PMCPMC6544442
OpenAlexW2894646707

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.